Literature DB >> 29880312

Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Elaine L Shelton1, Gautam K Singh2, Colin G Nichols3.   

Abstract

Forty years ago, non-steroidal anti-inflammatory drugs were first reported to decrease systemic prostaglandin levels and promote ductus arteriosus (DA) closure. And yet, prolonged patency of the DA (PDA) remains a significant clinical problem, complicated by imperfect therapies and wide variations in treatment strategy. There are few pharmacology-based tools available for treating PDA (indomethacin, ibuprofen, and acetaminophen), or for maintaining DA patency (PGE1) as is needed to facilitate corrective surgery for ductus-dependent congenital heart defects. Unfortunately, all of these treatments are inefficient and are associated with concerning adverse effects. This review highlights novel potential DA drug targets that may expand our therapeutic repertoire beyond the prostaglandin pathway.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  KATP channel; PDA; ductus arteriosus; novel drug targets

Mesh：

Substances：

Year:  2018        PMID： 29880312      PMCID： PMC6064654          DOI： 10.1053/j.semperi.2018.05.004

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN： 0146-0005            Impact factor:   3.300


  86 in total

1.  Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide.

Authors:  Fatma Demirel; Sevim Unal; I Ilker Çetin; Ihsan Esen; Aslihan Arasli
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

Review 2.  What makes a good drug target?

Authors:  Isabella Gashaw; Peter Ellinghaus; Anette Sommer; Khusru Asadullah
Journal:  Drug Discov Today       Date:  2011-09-16       Impact factor: 7.851

3.  Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less.

Authors:  Josh Koch; Gaynelle Hensley; Lonnie Roy; Shannon Brown; Claudio Ramaciotti; Charles R Rosenfeld
Journal:  Pediatrics       Date:  2006-04       Impact factor: 7.124

4.  Lamb ductus arteriosus: effect of prostaglandin synthesis inhibitors on the muscle tone and the response to prostaglandin E2.

Authors:  F Coceani; P M Olley; E Bodach
Journal:  Prostaglandins       Date:  1975-02

5.  Hereditary patent ductus arteriosus and its sequelae in the dog.

Authors:  D F Patterson; R L Pyle; J W Buchanan; E Trautvetter; D A Abt
Journal:  Circ Res       Date:  1971-07       Impact factor: 17.367

6.  A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.

Authors:  B Van Overmeire; K Smets; D Lecoutere; H Van de Broek; J Weyler; K Degroote; J P Langhendries
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

7.  Single nucleotide polymorphisms in AGTR1, TFAP2B, and TRAF1 are not associated with the incidence of patent ductus arteriosus in Japanese preterm infants.

Authors:  Koya Kawase; Tokio Sugiura; Yoshiaki Nagaya; Takaharu Yamada; Mari Sugimoto; Koichi Ito; Takao Togawa; Rika Nagasaki; Takenori Kato; Masanori Kouwaki; Norihisa Koyama; Shinji Saitoh
Journal:  Pediatr Int       Date:  2016-02-03       Impact factor: 1.524

8.  Genetic Modifiers of Patent Ductus Arteriosus in Term Infants.

Authors:  Priti M Patel; Allison M Momany; Kendra L Schaa; Paul A Romitti; Charlotte Druschel; Margaret E Cooper; Mary L Marazita; Jeffrey C Murray; John M Dagle
Journal:  J Pediatr       Date:  2016-06-22       Impact factor: 4.406

9.  Oxygen-induced tension in the sheep ductus arteriosus: effects of gestation on potassium and calcium channel regulation.

Authors:  Nahid Waleh; Jeff Reese; Hiroki Kajino; Christine Roman; Steven Seidner; Donald McCurnin; Ronald I Clyman
Journal:  Pediatr Res       Date:  2009-03       Impact factor: 3.756

10.  Effects of Advancing Gestation and Non-Caucasian Race on Ductus Arteriosus Gene Expression.

Authors:  Nahid Waleh; Anne Marie Barrette; John M Dagle; Allison Momany; Chengshi Jin; Nancy K Hills; Elaine L Shelton; Jeff Reese; Ronald I Clyman
Journal:  J Pediatr       Date:  2015-08-08       Impact factor: 4.406
View more
  5 in total

Review 1.  Kir6.1 and SUR2B in Cantú syndrome.

Authors:  Conor McClenaghan; Colin G Nichols
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

Review 2.  Role of Extracellular Matrix in Pathophysiology of Patent Ductus Arteriosus: Emphasis on Vascular Remodeling.

Authors:  Ting-Yi Lin; Jwu-Lai Yeh; Jong-Hau Hsu
Journal:  Int J Mol Sci       Date:  2020-07-04       Impact factor: 5.923

3.  Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity.

Authors:  Conor McClenaghan; Yan Huang; Zihan Yan; Theresa M Harter; Carmen M Halabi; Rod Chalk; Attila Kovacs; Gijs van Haaften; Maria S Remedi; Colin G Nichols
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 4.  To Feed or Not to Feed: A Critical Overview of Enteral Feeding Management and Gastrointestinal Complications in Preterm Neonates with a Patent Ductus Arteriosus.

Authors:  Silvia Martini; Arianna Aceti; Silvia Galletti; Isadora Beghetti; Giacomo Faldella; Luigi Corvaglia
Journal:  Nutrients       Date:  2019-12-27       Impact factor: 5.717

Review 5.  Mouse models of patent ductus arteriosus (PDA) and their relevance for human PDA.

Authors:  Michael T Yarboro; Srirupa H Gopal; Rachel L Su; Thomas M Morgan; Jeff Reese
Journal:  Dev Dyn       Date:  2021-08-14       Impact factor: 2.842
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.